Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy

Brenda Crabtree-Ramirez1, Cathy A. Jenkins2, Bryan E. Shepherd2, Karu Jayathilake2, Valdilea G. Veloso3, Gabriela Carriquiry4, Eduardo Gotuzzo4, Claudia P. Cortes5, Dennis Padgett6, Catherine McGowan7, Juan Sierra-Madero1, Serena Koenig7,8, Jean W. Pape8, Timothy R. Sterling2* and the CCASAnet Region of IeDEA

Abstract

Background: Some tuberculosis (TB) treatment guidelines recommend daily TB treatment in both the intensive and continuation phases of treatment in HIV-positive persons to decrease the risk of relapse and acquired drug resistance. However, guidelines vary across countries, and treatment is given 7, 5, 3, or 2 days/week. The effect of TB treatment intermittency in the continuation phase on mortality in HIV-positive persons on antiretroviral therapy (ART), is not well-described.

Methods: We conducted an observational cohort study among HIV-positive adults treated for TB between 2000 and 2018 and after enrollment into the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet; Brazil, Chile, Haiti, Honduras, Mexico and Peru). All received standard TB therapy (2-month initiation phase of daily isoniazid, rifampin or rifabutin, pyrazinamide±ethambutol) and continuation phase of isoniazid and rifampin or rifabutin, administered concomitantly with ART. Known timing of ART and TB treatment were also inclusion criteria. Kaplan–Meier and Cox proportional hazards methods compared time to death between groups. Missing model covariates were imputed via multiple imputation.

Results: 2303 patients met inclusion criteria: 2003 (87%) received TB treatment 5–7 days/week and 300 (13%) 2–3 days/week in the continuation phase. Intermittency varied by site: 100% of patients from Brazil and Haiti received continuation phase treatment 5–7 days/week, followed by Honduras (91%), Peru (42%), Mexico (7%), and Chile (0%). The crude risk of death was lower among those receiving treatment 5–7 vs. 2–3 days/week (HR = 0.68; 95% CI = 0.51–0.91; P = 0.008). After adjusting for age, sex, CD4, ART use at TB diagnosis, site of TB disease (pulmonary vs. extrapulmonary), and year of TB diagnosis, mortality risk was lower, but not significantly, among those treated 5–7 days/week vs. 2–3 days/week (HR 0.75, 95% CI 0.55–1.01; P = 0.06). After also stratifying by study site, there was no longer a protective effect (HR 1.42, 95% CI 0.83–2.45; P = 0.20).

Conclusions: TB treatment 5–7 days/week was associated with a marginally decreased risk of death compared to TB treatment 2–3 days/week in the continuation phase in multivariable, unstratified analyses. However, little variation in
Background

Intermittent therapy has been widely used in the continuation phase of first-line tuberculosis (TB) treatment, reducing medication and healthcare worker costs for TB programs, and facilitating global scale-up of directly observed therapy. [1–4] However, given the emergence of TB drug resistance and concerns regarding TB relapse, the World Health Organization (WHO) has recommended daily therapy as the preferred intermittency for TB treatment since 2008 [5, 6]. In addition, the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) recommended daily TB treatment for HIV-positive persons in 2016 [7]. However, guidelines vary across regions and countries, and treatment may be given 7, 5, 3, or 2 days/week in the continuation phase. For example, in Mexico and Argentina, TB treatment guidelines for HIV-positive persons recommend daily therapy during the initial two-month intensive phase and thrice-weekly therapy in the continuation phase [8–10]. In Brazil and Haiti, national recommendations include daily therapy in the continuation phase [11–14]. In Peru, previous national guidelines recommended intermittent treatment in the continuation phase, but more recently, daily therapy has been recommended [14].

Few studies have described the effect of TB treatment intermittency in the continuation phase on mortality in HIV-positive persons, particularly in persons receiving concomitant antiretroviral therapy (ART). In TB patients without HIV, systematic reviews have evaluated clinical outcomes according to different dosing frequencies. [15–17] Johnston and collaborators published a meta-analysis demonstrating that thrice-weekly dosing throughout TB treatment was associated with increased mortality compared to daily therapy. [16] Less frequent dosing schedules were significantly associated with an increased risk of TB relapse. In the meta-regression, they were also significantly associated with higher relapse rates, failure, and acquired drug resistance [16].

Several randomized, controlled trials (RCTs) have been published addressing first-line standard TB treatment, with few focusing on the intermittency of continuation phase treatment in HIV-negative patients [18–21]. More recently, a randomized clinical trial performed at several sites in South India concluded that in HIV-positive patients, daily anti-TB therapy throughout treatment for pulmonary TB was superior to thrice-weekly treatment throughout therapy, and thrice-weekly treatment in the continuation phase (with daily therapy in the intensive phase) [22]. However, the sample size was small, and hepatic toxicity risk was higher with daily therapy. Additionally, a prospective observational study concluded that thrice-weekly anti-TB therapy was effective in HIV-negative but not HIV-positive patients [23]. Patients who received directly observed intermittent anti-TB therapy during the intensive phase had a 40% higher risk of mortality than patients who received an unsupervised daily regimen [24]. Our group published an observational study assessing factors associated with mortality in TB/HIV co-infected patients. Duration of more than 6 months of TB treatment was associated with better survival than 6 months of treatment [25]. However, the description of frequency of intermittency in the continuation phase of TB treatment in HIV-positive persons in Latin America and its impact in survival has not been evaluated; data from large cohorts could provide important information for all settings, to confirm the data from the one clinical trial above. Given current recommendations that TB and HIV should be treated concomitantly, we focused on persons who received TB treatment and ART.

Methods

Cohort and overview

This study was performed in the Caribbean, Central and South America network for HIV Epidemiology (CCASAnet; http://ccasanet.vanderbilt.edu), which has been described elsewhere [26]. The collaboration was established in 2006 as part of IeDEA (International epidemiology Databases to Evaluate AIDS, https://www.idea.org/) to collect data from HIV-positive persons in care in Central and South America and the Caribbean. CCASAnet sites from Brazil, Chile, Haiti, Honduras, Mexico, and Peru were included. All sites are large, centralized, urban and public clinics; TB treatment was provided free of charge.

Institutional review board approval was obtained locally for each participating site and the CCASAnet data coordinating center (DCC) at Vanderbilt University Medical Center, Nashville, TN, USA. At each of the sites contributing data to this study, except IMTAvH-Peru, ethical regulations and policies permit retrospective analysis of de-identified clinical data without informed consent when research is approved by an Institutional Review
Board or appropriately constituted ethics committee. At IMTAvH-Peru, patients consent at the time of enrollment to provide de-identified clinical data for research studies.

**Study design and population**

All HIV-positive adults (≥ 18 years) diagnosed with TB on or after enrollment in CCASAnet and between 2000 and 2018 and whose initiation phase treatment for TB included: isoniazid (INH), rifampin (RIF) or rifabutin (RBT), and pyrazinamide (PZA), with or without ethambutol (EMB), were included in the analysis. Patients were followed until the first of last recorded date on which they were known to be alive prior to December 31, 2019 or their date of death. Tuberculosis treatment in the continuation phase had INH and RIF or RBT. Patients were categorized according to the frequency of TB treatment intermittency in the continuation phase (2–3/week vs. 5–7/week), following a recent meta-analysis [16]. Concomitant ART was determined by comparing the date of TB diagnosis and the end of the continuation phase of treatment with the ART start and stop dates; if there was any overlap, patients were considered to have received concomitant TB treatment and ART and included in the analysis. We excluded TB diagnoses prior to CCASAnet enrollment and patients with missing data on treatment intermittency, or whose ART was not concomitant with TB treatment. Only the first episode of TB after enrollment was included in the analysis. The date of TB diagnosis was the date of TB treatment initiation.

Missing treatment initiation phase stop dates were singly imputed to be 60 days after the treatment initiation start date; date of death or last day of follow-up if < 60 days. Missing treatment continuation phase stop dates were singly imputed to be 180 days after the treatment continuation phase start date; date of death or last day of follow-up if < 180 days.

**Outcome and statistical analysis**

Descriptive statistics on the entire cohort as well as those who had non-missing intermittency data were reported as median (interquartile range [IQR]) and percent (frequency), as appropriate. The primary outcome was time to death since TB diagnosis.

Unadjusted Kaplan–Meier survival curves and multivariable Cox proportional hazards models were used to investigate the association between time from TB diagnosis to death and frequency of continuation phase treatment (5–7x/week (referent) vs. 2–3x/week). Cox models included both unstratified and stratified by study site (i.e., the stratified Cox model allowed the baseline hazard to vary by site, but still estimated common regression coefficients pooled across sites) [25]. Cox models were adjusted for CD4 (square root transformed) and age at TB diagnosis, sex, site of TB (pulmonary only versus any extrapulmonary), timing of ART relative to the TB diagnosis (not on ART at TB diagnosis versus on ART at TB diagnosis), and year of TB diagnosis. CD4 at TB diagnosis was defined as the closest CD4 to the date of TB diagnosis within a window of 180 days before to 30 days after the diagnosis. Age, CD4 at TB diagnosis, and year of TB diagnosis were fit with restricted cubic splines (4 knots) to relax linearity assumptions with the specific point estimates informed by the distribution of our data. Missing model covariates were imputed using predictive mean matching (5 imputation replications). Univariate and multivariable models (complete case and multiply imputed analyses) were done. Sensitivity analyses of the Kaplan Meier curves were also done among those with pulmonary TB only, and among those receiving treatment in Peru. Statistical analyses were performed using R Statistical Software, Version 3.5.2 (www.R-project.org). Analysis code is posted at https://biostat.app.vumc.org/ArchivedAnalyses.

All methods were carried out in accordance with relevant guidelines and regulations.

---

**Fig. 1** Reasons for exclusion from the study population

- 3,451 were excluded
  - 2021 standard initiation (493) or continuation (1528) TB phase treatment was not initiated
  - 388 had been diagnosed prior to CCASAnet enrollment
  - 829 were not on ART concurrently with their TB treatment
  - 168 had an age of <18.0 years at TB diagnosis
  - 45 had missing intermittency data

- 54 subjects who met inclusion criteria and whose TB continuation phase treatment was 5 times per week were combined with those who received treatment 7 times per week

- 2,303 included in the final analysis
### Table 1  Clinical and demographic characteristics of the study population according to TB treatment intermittency frequency in the continuation phase

|                              | N = 300 | N = 2003 | N = 2303 | P-value |
|------------------------------|---------|----------|----------|---------|
| **Age at TB diagnosis—median (IQR)** | 34.80 (28.95, 42.61) | 36.61 (29.97, 44.82) | 36.41 (29.72, 44.38) | 0.021 |
| **Male sex** | 84% (251) | 55% (1107) | 59% (1358) | <0.001 |
| **CD4 at TB diagnosis—median (IQR)** | 97 (43, 196) | 173 (67, 310) | 156.5 (60, 295) | <0.001 |
| **Missing baseline CD4 indicator** | 9% (27) | 34% (674) | 30% (701) | <0.001 |
| **Baseline HIV-1 RNA (log10-transformed)** | 5.15 (4.70, 5.64) | 5.10 (4.55, 5.60) | 5.11 (4.63, 5.62) | 0.609 |
| **Site of TB** | 54% (163) | 78% (1556) | 75% (1719) | <0.001 |
| **CCASAnet site** | 0% (0) | 12% (245) | 11% (245) | <0.001 |
| **TB relative to ART** | 65% (196) | 59% (1188) | 60% (1384) | 0.047 |
| **Days on ART at TB diagnosis** | 46 (26.00, 79.25) | 28 (14, 63) | 30 (14, 67) | <0.001 |
| **Days from ART initiation post-TB dx to TB continuation stop** | 184 (1308, 251) | 168 (131, 190) | 168 (131, 197) | <0.001 |
| **Missing Initiation phase stop date** | 92% (275) | 100% (1999) | 99% (2274) | <0.001 |
| **Missing Continuation phase stop date** | 8% (25) | 0% (4) | 1% (29) | <0.001 |
| **Died** | 79% (238) | 89% (1783) | 88% (2021) | <0.001 |
| **Follow-up time (yrs)** | 6.55 (3.79, 8.89) | 3.61 (1.17, 6.49) | 4.03 (1.33, 7.13) | <0.001 |

IQR inter-quartile range, ART antiretroviral therapy, Wilcoxon Rank Sum test used for continuous covariates; Pearson chi-square test used for categorical variables

There were 2303 persons who met inclusion criteria.
Results

Population studied
There were 5754 HIV-positive TB patients in the CCASAnet cohort during the study period, of whom 3733 started standard 3- or 4-drug initial phase TB therapy and received isoniazid plus a rifamycin in the continuation phase. Of these, 2303 had a TB diagnosis after enrollment, were ≥ 18 years of age at that diagnosis, received concurrent TB treatment and ART, and had continuation phase treatment data available (Fig. 1). Clinical and demographic characteristics of those excluded vs. included in the analysis are shown in the supplemental material (Additional file 1). The median follow-up time was 4.0 (IQR 1.30, 7.10) years. There were 300 (13%) patients who received TB treatment 2–3 days per week and 2003 (87%) who received TB treatment 5–7 days per week in the continuation phase. (54 and 1949 patients received TB treatment 5 and 7 days per week, respectively) Table 1 provides the clinical and demographic characteristics of the overall study population, and according to treatment intermittency. Intermittency varied by site: 100% of patients from Brazil and Haiti received continuation phase treatment 5–7 days/week, followed by Honduras (91%), Peru (42%), Mexico (7%), and Chile (0%).

Mortality and associated factors
Among the 2303 TB patients included in the study, there were 282 deaths: (62 in the 2–3 days/week group and 220 in the 5–7 days/week group). Figure 2 shows the survival curves according to the frequency of TB treatment in the continuation phase; the crude risk of death was lower among the 5–7/week group (HR = 0.68; 95%
CI = 0.51—0.91; P = 0.008). After adjusting for age and CD4 at TB diagnosis, sex, site of TB (pulmonary only or any extrapulmonary), timing of ART, and year of TB diagnosis, the multivariable analysis that was not stratified by study site continued to demonstrate a reduction in mortality risk among persons who received TB treatment 5–7 days/week in the continuation phase (HR = 0.75, 95% confidence interval [CI] 0.55–1.01, p = 0.06) (Table 2). However, in the multivariable analysis stratified by study site, the hazard of death was elevated in the 5–7 days/week group (HR = 1.42, 95% CI 0.83–2.45; p = 0.2), though it was not statistically significant (Table 2).

In the stratified and unstratified multivariable analysis, increasing CD4 was associated with a decreased risk of death (p < 0.001 in both models). In contrast, increasing age was associated with an increased risk of death (p ≤ 0.01 in both models). In addition, being on ART at TB diagnosis was associated with an increased hazard of death when not stratifying by site (HR = 1.30, 95% CI 1.02–1.66, p = 0.03); however, this association was not statistically significant in the stratified analysis (HR = 1.23, 95% CI 0.96–1.59, p = 0.11). The risk of death decreased with more recent year of TB diagnosis (Table 2).

**Pulmonary tuberculosis**

There were 1719 (75%) patients with pulmonary TB only; 91% received continuation phase treatment 5–7 times per week, and they were mainly from Haiti, Brazil, and Peru. The Kaplan Meier curve among the pulmonary-only cohort showed that those with continuation phase treatment 5–7 times per week had higher survival than those in the 2–3 times per week group (p = 0.002) (Fig. 3).

### Analysis limited to Peru

The study site with the greatest diversity of treatment intermittency in the continuation phase was Peru. There were 175 persons who received treatment 5–7 times per week and 238 who received treatment 2–3 times per week. In a Kaplan–Meier analysis of these participants, the survival between the two groups was similar (uHR = 0.93, 95% CI = 0.59–1.54, p = 0.84; Fig. 4).

| Covariate | Not stratified by study site | | | Stratified by study site | | |
| --- | --- | --- | --- | --- | --- |
| | HR | 95% CI | P value | HR | 95% CI | P value |
| **Continuation phase frequency** | | | | | | |
| 2–3/week (ref) | 1.00 | – | 0.02 | 1.00 | – | 0.02 |
| 5–7/week | 0.71 | 0.52, 0.96 | 0.01 | 1.01 | 0.62, 1.63 | 0.01 |
| **Age at TB diagnosis (years)** | | | | | | |
| 30 | 1.08 | 0.97, 1.19 | 0.02 | 1.07 | 0.97, 1.19 | 0.02 |
| 35 (ref) | 1.00 | – | 0.02 | 1.00 | – | 0.02 |
| 40 | 1.07 | 0.90, 1.26 | 0.02 | 1.22 | 0.93, 1.59 | 0.02 |
| 45 | 1.21 | 0.92, 1.57 | 0.01 | 1.41 | 1.06, 1.87 | 0.01 |
| 50 | 1.37 | 1.03, 1.82 | 0.01 | 1.41 | 1.06, 1.87 | 0.01 |
| **Male sex** | | | | | | |
| Male sex | 0.90 | 0.70, 1.16 | 0.41 | 0.89 | 0.68, 1.15 | 0.36 |
| **CD4 at TB diagnosis** | | | | | | |
| 100 | 1.25 | 1.13, 1.39 | <0.001 | 1.25 | 1.13, 1.39 | <0.001 |
| 150 (ref) | 1.00 | – | 0.02 | 1.00 | – | 0.02 |
| 200 | 0.82 | 0.73, 0.92 | 0.02 | 0.82 | 0.73, 0.92 | 0.02 |
| 350 | 0.57 | 0.42, 0.77 | 0.02 | 0.56 | 0.42, 0.76 | 0.02 |
| **Site of TB** | | | | | | |
| Pulmonary only | 1.00 | – | 0.48 | 1.00 | – | 0.48 |
| Extrapulmonary TB | 0.91 | 0.69, 1.19 | 0.77 | 0.96 | 0.70, 1.30 | 0.77 |
| **ART relative to TB diagnosis** | | | | | | |
| Not on ART | 1.00 | – | 0.05 | 1.00 | – | 0.14 |
| On ART | 1.28 | 1.00, 1.63 | 0.04 | 1.21 | 0.94, 1.56 | 0.04 |

Analyses were performed both without and with stratification by study site; the latter to account for other potential differences by study site (n = 2288). Missing data were imputed via multiple imputation.

ART antiretroviral therapy
**Discussion**

In the present study, we assessed for differences in mortality in HIV-positive patients with TB depending on the intermittency of TB treatment in the continuation phase. There was a decreased mortality risk in patients who received treatment 5–7 days/week compared to 2–3 days/week, as evidenced by the crude risk of death in the Kaplan–Meier curves, and the multivariable Cox model that adjusted for age, sex, CD4 count, ART use at TB diagnosis, site of TB disease, and year of TB diagnosis. However, after stratifying by study site, there was no longer a protective effect. This suggests that there may have been other differences among sites that accounted for the difference in survival; this could include factors such as differences in ART, host factors, or access to specialized care. As expected, increased age and decreased CD4 count at diagnosis were statistically significant risk factors for mortality across all analyses. The risk of death increased even after TB treatment completion, which we have noted previously [26].

There was substantial variation across our sites in access to ART, treatment practices, and resources for treating HIV and TB co-infection. For example, sites had varying access to ART drug classes such as integrase strand transfer inhibitors, including raltegravir and more recently, dolutegravir. In addition, differences in HIV drug resistance patterns and resultant ART regimens could have also affected adherence and clinical outcomes [27–29]. Furthermore, local guidelines for treating TB and provider adherence to standards of care could vary within the region [9–13]. For instance, in Peru guidelines regarding treatment intermittency in the continuation phase changed over the study period.

![Survival curves dichotomized by continuation phase treatment frequency](image-url)
period—from 3 times per week to daily dosing [14]. In addition, since patients were not randomized to the different dosing intervals in our study, there may have been unmeasured confounding variables associated with mortality—as can occur in all observational studies [30]. Finally, there were differences in how many patients each center contributed to the study: Haiti (68%), Peru (18%), Brazil (11%), Chile (1.5%), Mexico (1.2%), and Honduras (1.0%) as well as differences in treatment frequency by site with the two largest contributors (Haiti and Brazil) administering treatment 5–7 days/week to all patients, consistent with their local guidelines [11–13].

Other studies have demonstrated that TB treatment given 2–3 days/week in the continuation phase is associated with an increased risk of relapse, treatment failure, and acquired drug resistance compared to treatment 5–7 days/week, most of which were conducted in HIV-negative persons [2, 15–17]. To date, only one randomized controlled clinical trial of TB treatment intermittency among HIV-positive persons has been conducted; it was performed in India and demonstrated superior efficacy and decreased emergence of drug resistance with daily dosing of TB medications throughout treatment [22]. This is also consistent with evidence from observational studies of HIV-negative persons. [15–17]. A retrospective cohort study in India among 292 HIV-TB coinfected patients on atazanavir/ritonavir compared outcomes among persons receiving daily rifabutin or thrice-weekly rifabutin during the TB treatment
continuation phase. More individuals in the daily group achieved clinical cure (73.0% vs. 44.1%, P < 0.001), with no significant differences in relapse/recurrence or all-cause mortality between groups. [31] The lack of a difference in all-cause mortality was similar to our findings in the multivariable analysis stratified by study site.

There were several limitations of our study. First, it was an observational cohort study. Although we performed multivariable analyses to adjust for potentially confounding variables, there may have been residual or unmeasured confounding that could affect study findings. There are other ways that we could have adjusted for confounding variables (e.g., inverse probability weighting), but these other approaches are also potentially sensitive to unmeasured confounding. We did not have information regarding TB treatment failure, TB relapse, nor cause of death. In addition, Latin America and the Caribbean include countries that span from low to high-income levels [32, 33], representing a heterogeneous group with varying access to TB diagnostic tests, TB treatment guidelines (even within countries during the period of study, e.g., Peru), and availability of treatment and care resources. However, this reflects the reality of clinical settings in Latin America and throughout the world. Our results are consistent with recent studies [16, 22, 31–33], but additional data are needed to inform the care of persons with HIV-related TB optimally. Prospective, randomized controlled trials of different TB treatment dosing intervals that include different regions in the globe affected by tuberculosis, would help identify the most effective and cost-effective regimens for TB treatment in persons with HIV who concomitantly receive ART.

Conclusion
Our study is one of the largest studies assessing possible associations between TB treatment intermittency in the continuation phase and mortality among persons with HIV on ART, and the only such study from Latin America and the Caribbean. In multivariable analysis, survival was improved among patients who received 5–7/week dosing. However, after then stratifying by study site, the protective effect was no longer observed. This was perhaps due to heterogeneity in clinical practice at the different study sites or unmeasured confounding. Our study suggests that TB treatment dosing 5–7 days/week during the continuation phase of treatment could reduce mortality in HIV-positive patients, but prospective randomized trials are needed.

Abbreviations
TB: Tuberculosis; ART: Antiretroviral therapy; CCASAnet: Caribbean, Central and South America network for HIV epidemiology; WHO: World Health Organization; CDC: Centers of Disease Control and Prevention; IDSA: Infectious Diseases Society of America; RTC: Randomized controlled trial; IeDEA: International epidemiology Databases to Evaluate AIDS; DCC: Data Coordinating Center; INH: Isoniazid; RIF: Rifampin; RBT: Rifabutin; PZA: Pyrazinamide; EMB: Ethambutol; IQR: Interquartile range.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07330-5.

Additional file 1: Table S1. Clinical and demographic characteristics of those excluded vs. included in the analysis. Table that indicates clinical and demographic characteristics of those excluded vs. included dichotomized by continuation phase treatment.

Acknowledgements
We thank the staff at each of the CCASANET centers and especially our patients. The Caribbean, Central and South American network for HIV epidemiology (CCASAnet) includes research teams in the following sites: Fundación Huésped, Argentina: Pedro Cahn, Carina Cesar, Valeria Fink, Zulma Ortiz, Florencio Cahn, Agustina Roldan, Ines Aristegui, Claudia Flora. Instituto Nacional de Infectología-Fiocruz, Brazil: Beatriz Grinsztejn, Valdilea G. Veloso, Paula M. Luz, Sandra Cardoso Wagner, Ruth Friedman, Ronaldo I. Moreira, Lara Esteves Coelho, Monica Derrico Pedrosa, Guillerme Amaral Calvet, Hugo Perazzo, Rodrigo Moreira, Maria Pia Diniz Ribeiro, Mario Sergio Pereira, Emilia Moreira Jalil. Universidad Federal de Minas Gerais, Brazil: Jorge Pinto, Flavia Ferreira, Marcella Maia. Universidad Federal de Sao Paulo, Brazil: Regina Célia de Menezes Succi, Daisy Maria Machado, Aida de Fátima Barbosa Gouveia, Fabiana do Carmo. Fundación Arriarán, Chile: Claudia Cortes, Marcelo Wolff, Maria Fernanda Rodriguez, Gabriel Castillo, Gladys Allendes. Les Centres GHSKIO, Haiti: Jean William Pape, Vanessa Rouzier, Adias Marcelin, Youy Macius, Stephano Saint Preux. Hospital Escuela Universitario, Honduras: Marco Tulio Luque, Diana Varela, Magda Chavez, Ada Mailhot. Instituto Hondureño de Seguridad Social, Honduras: Denis Padgett. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico: Juan Sierra Madero, Brenda Crabtree Ramirez, Yanik Caro Vega. Instituto de Medicina Tropical Alexander von Humboldt, Peru: Eduardo Gotuzzo, Fernando Mejia, Gabriela Carriquiry. Vanderbilt University Medical Center, USA: Catherine C McGowan, Stephany N Duda, Bryan E Shepherd, Timothy Sterling, Anna K Person, Peter F Rebeiro, Jessica Castilho, William C Wester, Kate Clouse, Karu Jayathilake, Fernanda Maruri, Hilary Vansell, Marina Crunivel Figueredo, Cathy Jenkins, Ahra Kim, Sarah Lotzpeich, Paridhi Ranadive. Vanderbilt University, USA: Kate Clouse.

“CCASAnet Region 2 of IeDEA” Consortium members: Argentina – Fundación Huésped: Pedro Cahn, Carina Cesar, Valeria Fink, Zulma Ortiz, Florencio Cahn, Agustina Roldan, Ines Aristegui, Claudia Flora. Brazil – Instituto Nacional de Infectologia-Fiocruz: Beatriz Grinsztejn, Valdilea G. Veloso (Author), Paula M. Luz, Sandra Cardoso Wagner, Ruth Friedman, Ronaldo I. Moreira, Lara Esteves Coelho, Monica Derrico Pedrosa, Guillerme Amaral Calvet, Hugo Perazzo, Rodrigo Moreira, Maria Pia Diniz Ribeiro, Mario Sergio Pereira, Emilia Moreira Jalil. – Universidad Federal de Minas Gerais: Jorge Pinto, Flavia Ferreira, Marcella Maia. – Universidad Federal de Sao Paulo: Regina Célia de Menezes Succi, Daisy Maria Machado, Aida de Fátima Barbosa Gouveia, Fabiana do Carmo. Chile – Fundación Arriarán: Claudia Cortes (Author), Marcelo Wolff, Maria Fernanda Rodriguez, Gabriel Castillo, Gladys Allendes. Haiti – Les Centres GHSKIO: Jean William Pape (Author), Vanessa Rouzier, Adias Marcelin, Youy Macius, Stephano Saint Preux, Serena Koenig (Author). Honduras – Hospital Escuela Universitario: Marco Tulio Luque, Diana Varela, Magda Chavez, Ada Mailhot. Instituto Hondureño de Seguridad Social: Denis Padgett (Author). Mexico – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán: Juan Sierra Madero (Author), Brenda Crabtree Ramirez (Author), Yanik Caro Vega. Peru – Instituto de Medicina Tropical Alexander von Humboldt: Eduardo Gotuzzo (Author), Fernando Mejia, Gabriela Carriquiry (Author). USA – Vanderbilt University Medical Center: Catherine C McGowan (Author), Stephany N Duda, Bryan E Shepherd (Author), Timothy Sterling (Author), Anna Crabtree-Ramirez et al. BMC Infectious Diseases          (2022) 22:341
K Person, Peter F Rebeiro, Jessica Castiño, William C Wester, Kate Clouse, Karu Jayathilake (Author), Fernanda Maruri, Hilary Vansell, Marina Cruvinel Figueiredo, Cathy Jenkins (Author), Afra Kim, Sarah Lottspeich, Paridhi Ranadive.

Vanderbilt University: Kate Clouse.

Author contributions

TRS, BCR, BES and CJ contributed to the study design, data analysis and drafted the manuscript. TRS, BCR, GC, DP, EG, JSM, VV, CM, KJ, CC, SK and JP are investigators of CCASAnet project, they contributed to the study design and data collection. All authors contributed to the interpretation of the study results. All authors are members of the CCASAnet consortia. All authors read and approved the final manuscript.

Funding

This work was supported by the NIH-funded Caribbean, Central and South America network for HIV epidemiology (CCASAnet), a member cohort of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) (U01AI069923). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This award is funded by the following institutes: National Institute Of Allergy And Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Heart, Lung, And Blood Institute (NHBLI), National Institute Of Diabetes And Digestive-And Kidney Diseases (NDDK), National Institute On Drug Abuse (NIDA), National Institute On Alcohol Abuse And Alcoholism (NIAAA), Fogarty International Center (FIC), and National Cancer Institute (NCI).

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Institutional review board approval was obtained locally for each participating site for the constitution of the CCASAnet cohort, and data are coordinated by the Vanderbilt University Medical Center, Nashville, TN, USA. At each of the sites contributing data for this study, except the participant site in Peru (Instituto de Medicina Tropical Alexander von Humboldt, IMTAvH), the ethic Committee of Instituto Nacional de Infectologia Evandro Chagas, in Brazil, the Ethic Committee of Fundación Arriarán, in Chile; the ethic Committee of Le Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO), in Haiti; the Ethic Committee of Hospital Escuela and Instituto Hondureño de Seguridad Social, in Honduras; and the Ethic Committee of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, in Mexico permit retrospective analysis of de-identified clinical data without informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Departamento de Infectología. Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico.
2 Vanderbilt University Medical Center, A2209 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232, USA.
3 Instituto Nacional de Infectología Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
4 Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
5 Fundación Arriarán, University of Chile, Santiago, Chile.
6 Hospital Escuela and Instituto Hondureño de Seguridad Social, Tegucigalpa, Honduras.
7 División de Global Health Equity, Brigham and Women’s Hospital, Boston, MA, USA.
8 Le Groupe Haitien d’Etude du Sarcome de Kaposi Et Des Infections Opportunistes (GHESKIO), Port-au-Prince, Haiti.

Received: 21 September 2021 Accepted: 28 March 2022

Published online: 05 April 2022

References

1. Ahmad F, Milion J, Al-Motair A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis. 2012;55(8):1154–63.
2. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174(10):1153–8.
3. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J Suppl. 2002;36:787–94s.
4. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. Ann Intern Med. 1990;12(6):407–15. doi https://dx.doi.org/10.7326/0003-4819-76-3-112-6-407.
5. World Health Organization WH. Global Tuberculosis Programme. WHO treatment guidelines for drug-resistant tuberculosis : 2016 update. Who. 2016:56.
6. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Department of HIV/AIDS. Stop TB Department. World Health Organization. 2008.
7. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–95.
8. Salud M De. Atención Integral De Las Personas Afectadas Por Tuberculosis 2013:1:172.
9. Guia de Práctica Clínica, Diagnóstico y Tratamiento de Casos Nuevos de Tuberculosis Pulmonar. México: Secretaría de Salud, 2009.
10. Bossio JC, Moral M, Arias S, Barrientas L, Imaiz M. Enfermedades Infecciosas, Tuberculosis. Guía para el Equipo de Salud. Enfermedades Infecc. 2009;21(8):S1.
11. Ministério da saúde. Recomendações para o manejo da coinfecção TB-HIV em serviços de atenção especializada a pessoas vivendo com HIV/ AIDS. Secretaria Executiva-Brasília. Ministério da saúde 2013:1–30.
12. Guide BB, Gibson BT. Guía Básico para prevención, diagnóstico e tratamiento de la tuberculosis en personas viviendo con HIV. Programa Estadual DST/AIDS SP. 2017;1:7–19.
13. Ministere de la Sante Publique et de la Population. Manuel de normes du programme national de lutte contre la tuberculose; Direction de la Prévention, 2010.
14. de Salud Ministerio, del Perú República. Norma Técnica de Salud para la Prevención y Control de la coinfeción Tuberculosis y Virus de la Inmunodeficiencia Humana en el Perú. Ministerio de Salud MINSA/DGIESP. 2018;143:1.
15. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PloS Med. 2009;6(9):e1000150.
16. Johnston JC, Campbell JR, Menzies D. Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and metaanalysis. Clin Infect Dis. 2017;64(9):1211–20.
17. Kasozi S, Clark J, Doi SA. Intermittent versus daily pulmonary tuberculosis treatment regimens: a meta-analysis. Clin Med Res. 2015;13(3–4):117–38.
18. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. REMoxTB Consortium. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87.
19. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–63.
20. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al. Trial Group. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA. 2011;305(14):1415–23.
21. Merle CS, Fielding K, Sow OB, Grinafon M, Lo MB, Mthiyane T, et al. OcloTUB/Gatifloxacin for Tuberculosis Project A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98.
22. Gopalan N, Santhanakrishnan RK, Palaniappan AN, Menon PA, Lakshman S, Chandrasekaran P, et al. Daily vs. intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: a randomized clinical trial. JAMA Intern Med. 2018;178(4):485–93.

23. Vashishtha R, Mohan K, Singh B, Devarapu SK, Sreenivas V, et al. Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study. BMC Infect Dis. 2013;7(13):468.

24. Alvarez-Uria G, Midde M, Pakam R, Naik PK. Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients. Biomed Res Int. 2014;2014:937817.

25. Giganti MJ, Luz PM, Caro-Vega Y, Cesar C, Padgett D, Koenig S, Echevarria J, McGowan CC, Shepherd BE. A comparison of seven Cox regression-based models to account for heterogeneity across multiple HIV treatment cohorts in Latin America and the Caribbean. AIDS Res Hum Retroviruses. 2015;31:496–503.

26. Koenig SP, Kim A, Shepherd BE, et al. Increased mortality after tuberculosis treatment completion in persons living with human immunodeficiency virus in Latin America. Clin Infect Dis. 2020;71(1):215–7. https://doi.org/10.1093/cid/ciaa1032.

27. Cortes CP, Wéhbe FH, McGowan CC, Shepherd BE, Duda SN, Jenkins CA, et al. Caribbean, Central American, South American Network for HIV Research of the International Epidemiologic Databases to Evaluate AIDS. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis. PLoS One. 2013;8(9):e74057.

28. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, Schechter M. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007;36(S):969–76.

29. Murphy RA, Marconi VC, Gandhi RT, Kurtzkes DR, Sunpath H. Co-administration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS ONE. 2012;7(9):e44793.

30. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14(8):1039–43.

31. Caro-Vega Y, Schultz A, Efsen AM, et al. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. BMC Infectious Diseases. 2018;18:191. https://doi.org/10.1186/s12879-018-3077-x.

32. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, et al. Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol. 2016;45(6):2038–49.

33. Jenks JD, Kumarasamy N, Ezharasi C, Poongulali S, Ambrose P, Yepthomi T, et al. Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India. Int J Tuberc Lung Dis. 2016;20(9):1181–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.